Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has provided an announcement.
Hangzhou Tigermed Consulting Co., Ltd. has released its third quarterly report for the financial year 2025. The report, prepared in accordance with Chinese accounting standards, remains unaudited and highlights the company’s ongoing operations. This announcement is crucial for shareholders and public investors, providing insights into the company’s financial health and strategic direction.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$62.10 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates in the consulting industry, providing services related to clinical research and development for the pharmaceutical and biotechnology sectors.
Average Trading Volume: 3,001,623
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.56B
For detailed information about 3347 stock, go to TipRanks’ Stock Analysis page.